Navigation Links
Renhuang Announces Appointment of Interim CFO
Date:8/20/2010

Renhuang Announces Appointment of Interim CFO -- HARBIN, China, Aug. 20 /PRNewswire-Asia-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Personnel Announcements Click to view news release full screen  

Renhuang Announces Appointment of Interim CFO

 

HARBIN, China, Aug. 20 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (NYSE Amex: CBP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that, it has appointed Ms. Xiaoying Lu as its Interim Chief Financial Officer ("CFO"), while the Company seeks a permanent replacement.

Reporting directly to Mr. Shaoming Li, the Company's Chairman and Chief Executive Officer, Ms. Lu will be responsible for managing all financial functions, including, financial management, reporting, risk management and managing the financial budget, while Renhuang continues to search for a new CFO. Upon his or her appointment, Ms. Lu will transition to the role of an Assistant to the CFO to ensure a seamless transition.

Prior to joining Renhuang's financial department on August 13, Ms. Lu was director of accounting at Harbin Santong Energy Limited Company, an enterprise with more than 500 employees, where she served for over six years. Ms. Lu graduated from Harbin Institute of Economic Management with a Bachelor's degree in Accounting. She is a certified Senior Accountant, which requires passing the national senior accountant exam and meeting rigorous standards for work experience and foreign language skills. Ms. Lu is also in process of completing the requisites to earn her China CPA (Certified Public Accountant).

"We are excited to have Ms. Lu as part of Renhuang's management team and extend a warm welcome to her. Her professional experience will make her a valuable asset to our finance team," said Mr. Shaoming Li, the Company's Chairman and Chief Executive Officer. "We have tremendous confidence in her ability to manage Renhuang's finance operations during this interim period, particularly because she shares Renhuang's dedication and commitment to instituting and maintaining high standards of accuracy and transparency."

About Renhuang Pharmaceuticals, Inc.

Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs. through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. Company Website: http://www.renhuang.com .

Safe Harbor Statement

This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to manage expansion of its operations effectively, ability to find a new CFO, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

For more information, please contact: Company Contact: Renhuang Pharmaceuticals, Inc. Ms. Portia Tan, IR Contact Phone: +86-451-8260-2162 Email: ir@renhuang.com CCG Investor Relations: Mr. Mark Collinson, Partner Phone: +1-310-954-1343 (Los Angeles) Email: mark.collinson@ccgir.com Web: http://www.ccgirasia.com Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: crocker.coulson@ccgir.com
'/>"/>

SOURCE Renhuang Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Renhuang Receives Patent for Product Package Design for Compound Honeysuckle Granules
2. Renhuang Showcases its All Natural Products at 45th China National New and Special Drugs Fair
3. Renhuang Signs Exclusive Purchase Agreement for Siberian Ginseng
4. Renhuang Begins Trading on NYSE Amex
5. Renhuang Pharmaceuticals Receives Approval to List on the NYSE Amex
6. Renhuang Pharmaceuticals Exhibits Siberian Ginseng Products at the 21st China Harbin International Economic and Trade Fair
7. Renhuang to Launch New Bio-pharmaceutical Product - Ginseng and Deer Antler Extract
8. Renhuang to Launch New All-Natural Anti-depressant and Nerve Regulation Product - Compound Schisandra Tablets
9. Renhuang Wins Bid to Supply All-Natural Products to Guangzhou Military District
10. Renhuang Schedules Conference Call to Discuss FY 2010 Second Quarter Results
11. Renhuang Appoints PricewaterhouseCoopers to Develop a SOX 404 Compliance Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... -- Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet die ... chinesischen Provinz Guizhou, 2017 mit dem Angebot von Anreize schaffenden ... Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. Foto - http://mma.prnewswire.com/media/471342/First_CRH__CHina_Railway_High_Speed__Train_Enters_Guian.jpg ... ... ...
(Date:2/23/2017)... 2017 Research and Markets has announced the ... 2016" report to their offering. ... The latest research Fibromyalgia Drugs Price Analysis ... the global Fibromyalgia market. The research answers the following ... for Fibromyalgia and their clinical attributes? How are they positioned in ...
(Date:2/23/2017)... LA JOLLA, Calif. , Feb. 23, 2017 /PRNewswire/ ... biopharmaceutical company leading the discovery and development of innovative ... quarter and full year 2016 financial results on Thursday, ... Regulus will host a conference call and webcast on ... discuss fourth quarter and full year 2016 financial results ...
Breaking Medicine Technology:
(Date:2/24/2017)... Abilene, Texas (PRWEB) , ... February 24, 2017 , ... ... article that focuses on Bible Prophecy concerning this present generation. Yisrayl makes an ... of this current generation. He explains that the Bible details the current times ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... Senior International Elite division on February 12th. Ms. Esparza qualified into this ... elite qualifier competition held in Las Vegas, Nevada. Frida is one of approximately ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Country Club in Miami Beach to host its Swirl: Miami Wine Tasting Event ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a ... content marketing, social media management, corporate communications, SEO and cause marketing, is opening ... in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
Breaking Medicine News(10 mins):